跳至內容區
苗栗心安診所

苗栗心安診所

心安用心,全家安心

  • 首頁
  • 最新文章
  • 門診時刻表
    • 頭份心安門診表
  • 服務項目
  • 疫苗注射
  • 醫療團隊成員(醫師)
    • 護理師衛教師(CDE)
    • 營養師
    • 藥師
    • 糖尿病衛教師(CDE)專業認證人員
  • 新聞媒體專訪
  • 教學影片區
  • 醫療相關認證
  • 楊宗衡院長學術討論會
    • 舞台上的醫學思辨:楊宗衡醫師主持剪影
    • 陳嘉偉院長學術研討會
    • 民眾衛教演講
  • 病人好評
  • 雲端號碼
  • youtube
  • 苗栗FB
  • 頭份FB
  • 苗栗Line
  • 頭份Line

標籤彙整: gout

Gout and Metabolic Syndrome: The Interconnection of Uric Acid, Obesity, and Lipids

Investigate the relationship between hyperuricemia, insulin resistance, visceral obesity, and dyslipidemia in patients with gout.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:dyslipidemia,gout,insulin resistance,lipids,metabolic syndrome,obesity

Colchicine in Acute Gout Flares: Dosing, Side Effects, and the Safety Window

Understand colchicine dosing, mechanisms, and safety margins for acute gout flares. Learn how the AGREE trial transformed clinical dosing and how to avoid severe drug-drug interactions.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:AGREE trial,colchicine,drug safety,flare-up,gout,pharmacotherapy

NSAIDs and Systemic Corticosteroids for Gout Flares: Efficacy and Precautions

Compare the clinical efficacy and safety of NSAIDs versus systemic corticosteroids for acute gout flares. Learn how patient comorbidities dictate the choice between these options.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:corticosteroids,flare-up,gout,kidney safety,nsaids,prednisone

Allopurinol: First-Line Urate-Lowering Therapy (ULT) and Titration Targets

Discover why allopurinol is the preferred first-line treatment for chronic gout. Learn the clinical rationale for gradual titration and targeted urate lowering.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:allopurinol,gout,titration,treat-to-target,urate lowering therapy,xanthine oxidase inhibitor

Febuxostat (Uloric): An Alternative ULT for Patients and Cardiovascular Warnings

Understand febuxostat as an alternative urate-lowering therapy. Explore the pharmacology, clinical trials (CARES and FAST), and the context of its FDA Boxed Warning.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:cardiovascular risk,CARES trial,FAST trial,febuxostat,gout,Uloric

Benzbromarone and Uricosuric Agents: Enhancing Kidney Uric Acid Excretion

Explore benzbromarone and uricosuric agents in gout management. Learn their mechanism of action, regional availability, and precautions to prevent kidney stones.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:benzbromarone,gout,kidney function,probenecid,renal clearance,uricosurics

Allopurinol Hypersensitivity Syndrome (AHS): HLA-B*5801 Testing and Severe Rashes

Learn about the clinical features of Allopurinol Hypersensitivity Syndrome (AHS) and the importance of HLA-B*5801 genetic screening before starting therapy.

分類:楊宗衡總院長2026-06-19發表於醫療衛教文章標籤:allopurinol,genetic testing,gout,HLA-B*5801,hypersensitivity,SJS/TEN

Uric Acid and Heart Disease: Is Hyperuricemia an Independent Risk Factor?

Review the clinical evidence, vascular mechanisms, and debate surrounding hyperuricemia as an independent risk factor for cardiovascular disease.

分類:楊宗衡總院長2026-06-18發表於醫療衛教文章標籤:allopurinol,atherosclerosis,cardiovascular,gout,heart disease,hypertension

Co-Managing Gout and Chronic Kidney Disease (CKD): Dosing Adjustments

A clinical guide to adjusting allopurinol and flare medications safely in patients with concurrent gout and chronic kidney disease.

分類:楊宗衡總院長2026-06-18發表於醫療衛教文章標籤:allopurinol,CKD,colchicine,gout,kidney disease,renal dosing

Diuretic-Induced Hyperuricemia: How Blood Pressure Meds Impact Uric Acid

Examine the renal mechanisms of diuretic-induced hyperuricemia and identify safe antihypertensive alternatives for gout patients.

分類:楊宗衡總院長2026-06-18發表於醫療衛教文章標籤:diuretics,gout,hypertension,kidneys,losartan,side effects

文章分頁

較新的文章 1 2 3 較舊的文章

根據醫療機構的網際網路資訊管理規範,禁止網際網路服務供應商複製或轉載本網站內容以供公眾閱覽。但是通過網路搜索或透過超連結直接訪問本醫療機構的網站,則此項限制不適用。

  • 首頁
  • 歷史發展
  • 聯絡我們
  • 徵才專區
  • 交通資訊
苗栗心安診所, 在 WordPress.com 建立網站或網誌 隱私權政策